US equities |
SPCX $171.09 ▲+0.00% NVDA $238.90 ▲+0.00% MU $1,063.96 ▲+0.00% SKHY $195.02 ▲+0.00% SNDK $1,704.16 ▲+0.00% TSLA $378.73 ▲+0.00% INTC $116.19 ▲+0.00% AVGO $362.51 ▲+0.00%
FinancialContent

Articles published by Atreca, Inc.

News headline image
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL IMNM
News headline image
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca to Participate at Cowen’s 43rd Annual Health Care Conference
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca to Present at Upcoming Investor Conferences
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL
News headline image
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Atreca, Inc.
Via GlobeNewswire
Tickers BCEL